Drug Profile
Research programme: transmucosal therapeutics - Endo
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Auxilium Pharmaceuticals
- Developer Endo International
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bladder dysfunction; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bladder-dysfunction in USA (Transmucosal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (Transmucosal)
- 29 Jan 2015 Auxilium Pharmaceuticals has been acquired by Endo International